Homocysteine modulates the effect of simvastatin on expression of ApoA-I and NF-κB/iNOS

Cardiovascular Research

Volumn 80, Issue 1, 2008, Pages 151-158

  Mikael, Leonie G ^a   Rozen, Rima ^a  

^a RESEARCH INSTITUTE OF THE MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

Author keywords

Apolipoprotein AI; Homocysteine; Inducible nitric oxide synthase; MTHFR; Nuclear factor B; Statin

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); APOLIPOPROTEIN A1; CHOLESTEROL; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HOMOCYSTEINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; MESSENGER RNA; SIMVASTATIN;

AMINO ACID BLOOD LEVEL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CELL STRAIN HEPG2; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIET; DRUG EFFICACY; DRUG MECHANISM; ENZYME ACTIVITY; FEMALE; GENE SEQUENCE; HUMAN; HUMAN CELL; HYPERHOMOCYSTEINEMIA; IN VIVO STUDY; INFLAMMATORY CELL; INJECTION; LIVER CELL CARCINOMA; MACROPHAGE; MALE; METHYLENETETRAHYDROFOLATE REDUCTASE DEFICIENCY; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN MODIFICATION; PROTEIN SYNTHESIS; PROTEIN TARGETING; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SINGLE DRUG DOSE; WESTERN BLOTTING;

ANIMALS; APOLIPOPROTEIN A-I; CELL LINE, TUMOR; CHOLESTEROL; FEMALE; HOMOCYSTEINE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LEUKOCYTES, MONONUCLEAR; MALE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MICE; MICE, INBRED C57BL; NITRIC OXIDE SYNTHASE TYPE II; PROMOTER REGIONS, GENETIC; SIMVASTATIN; TRANSCRIPTION FACTOR RELA;

EID: 51749113619     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvn157     Document Type: Article

References (37)

1. Grundy S, Cleeman J, Merz C, Brewer HJ, Clark L, Hunninghake D et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Circulation 2004;110:227-239.
2. Maron D, Fazio S, Linton M. Current perspectives on statins. Circulation 2000;101:207-213.
3. Mangravite L, Thorn C, Krauss R. Clinical implications of pharmacogenomics of statin treatment. Pharmacogenomics J 2006;6:360-374.
4. Landmesser U, Bahlmann F, Mueller M, Spiekermann S, Kirchhoff N, Schulz S et al. Simvastatin versus Ezetimibe: pleiotropic and lipid-lowering effects on endothelial function in humans. Circulation 2005;111:2356-2363.
5. Liao J. Beyond lipid lowering: the role of statins in vascular protection. Int J Cardiol 2002;86:5-18.
6. Vaughan C, Delanty N. Neuroprotective properties of statins in cerebral ischemia and stroke. Stroke 1999;30:1969-1973.
7. Wierzbicki A. Homocysteine and cardiovascular disease: a review of the evidence. Diabetes Vasc Dis Res 2007;4:143-150.
8. Refsum U, Ueland PM, Nygård O, Vollset SE. Homocysteine and vascular disease. Ann Rev Med 1998;49:31-62.
9. Frosst P, Blom H, Milos R, Goyette P, Sheppard C, Matthews R et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 1995;10:111-113.
10. Mikael LG, Genest J Jr, Rozen R. Elevated homocysteine reduces Apolipoprotein A-I expression in Hyperhomocysteinemic mice and in males with coronary artery disease. Circ Res 2006;98:564-571.
11. Krause B, Princen H. Lack of predictability of classical animal models for hypolipidemic activity: a good time for mice? Atherosclerosis 1998;140:15-24.
12. Johnston T, Nguyen L, Chu W, Shefer S. Potency of select statin drugs in a new mouse model of hyperlipidemia and atherosclerosis. Int J Pharm 2001;229:75-86.
13. Mitchell A, Fidge N, Griffiths P. The effect of HMG-CoA reductase inhibitor simvastatin and of cholestyramine on hepatic apolipoprotein mRNA levels in the rat. Biochim Biophys Acta 1993;1167:9-14.
14. Navab M, Anantharamaiah G, Hama S, Hough G, Reddy S, Frank J et al. D-4F and Statins synergize to render HDL antiinflammatory in mice and monkeys and cause lesion regression in old Apolipoprotein E-Null mice. Arterioscler Thromb Vasc Biol 2005;25:1426-1432.
15. Wang G, Siow YL, O K. Homocysteine stimulates nuclear factor kappaB activity and monocyte chemoattractant protein-1 expression in vascular smooth-muscle cells: a possible role for protein kinase C. Biochem J 2000;352:817-826.
16. Napoli C, Ignarro L. Nitric oxide and atherosclerosis. Nitric Oxide 2001;5:88-97.
17. Nunokawa Y, Ishida N, Tanaka S. Promoter analysis of human inducible nitric oxide synthase gene associated with cardiovascular homeostasis. Biochem Biophys Res Commun 1994;200:802-807.
18. Au-Yeung KKW, Woo CWH, Sung FL, Yip JCW, Siow YL, O K. Hyperhomocysteinemia activates nuclear factor-KB in endothelial cells via oxidative stress. Circ Res 2004;94:28-36.
19. Welch GN, Upchurch GR, Fariver RS, Pigazzi A, Vu K, Brecher P et al. Homocysteine-induced nitric oxide production in vascular smooth-muscle cells by NF-kappa-B-dependent transcriptional activation of Nos2. Proc Assoc Am Physicians 1998;110:22-31.
20. Dichtl W, Dulak J, Frick M, Alber HF, Schwarzacher SP, Ares MPS et al. HMG-CoA reductase inhibitors regulate inflammatory transcription factors in human endothelial and vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 2003;23:58-63.
21. Hernández-Presa M, Ortego M, Tuñón J, Martín-Ventura J, Mas S, Blanco-Colio L et al. Simvastatin reduces NF-κB activity in peripheral mononuclear and in plaque cells of rabbit atheroma more markedly than lipid lowering diet. Cardiovasc Res 2003;57:168-177.
22. Huang KC, Chen CW, Chen JC, Lin WW. HMG-CoA reductase inhibitors inhibit inducible nitric oxide synthase gene expression in macrophages. J Biomed Sci 2003;10:396-405.
23. Chen J-C, Huang K-C, Lin W-W. HMG-CoA reductase inhibitors upregulate heme oxygenase-1 expression in murine RAW264.7 macrophages via ERK, p38 MAPK and protein kinase G pathways. Cell Signal 2006;18:32-39.
24. Habara K, Hamada Y, Yamada M, Tokuhara K, Tanaka H, Kaibori M et al. Pitavastatin upregulates the induction if iNOS through enhanced stabilization of its mRNA in proinflammatory cytokine-stimulated hepatocytes. Nitric Oxide 2008;18:19-27.
25. Schwahn BC, Wang X-L, Mikael LG, Wu Q, Cohn J, Jiang H et al. Betaine supplementation improves the atherogenic risk factor profile in a transgenic mouse model of hyperhomocysteinemia. Atherosclerosis 2007;195:e100-e107.
26. Leclerc D, Rozen R. Endoplasmic reticulum stress increases the expression of Methylenetetrahydrofolate reductase through the IRE1 transducer. J Biol Chem 2008;283:3151-3160.
27. Paumelle R, Blanquart C, Briand O, Baribier O, Duhem C, Woerly G et al. Acute antiinflammatory properties of statins involve peroxisome proliferator-activated receptor-alpha via inhibition of the protein kinase C signalling pathway. Circ Res 2006;98:361-369.
28. Sharma P, Senthilkumar R, Brahmachari V, Sundaramoorthy E, Mahajan A, Sharma A et al. Mining literature for a comprehensive pathway analysis: a case study for retrieval of homocysteine related genes for genetic and epigenetic studies. Lipids Health Dis 2006;5:1-19.
29. Martin G, Duez H, Blanquart C, Berezowski V, Poulain P, Fruchart J-C et al. Statin-induced inhibition of the Rho-signaling pathway activates PPAR-alpha and induces HDL ApoA-I. J Clin Invest 2001;107:1423- 1432.
30. Bonn V, Cheung R, Chen B, Taghibiglou C, van Iderstine S, Adeli K. Simvastatin, an HMG-CoA reductase inhibitor, induces the synthesis and secretion of apolipoprotein AI in HepG2 cells and primary hamster hepatocytes. Atherosclerosis 2002;163:59-68.
31. Liao D, Tan H, Hui R, Li Z, Jiang X, Gaubatz J et al. Hyperhomocysteinemia decreases circulating high-density lipoprotein by inhibiting apolipoprotein A-I protein synthesis and enhancing HDL cholesterol clearance. Circ Res 2006;99:598-606.
32. Miltiadous G, Papakostas J. Statins and homocysteine. Atherosclerosis 2003;166:199-200.
33. Ridker P, Shih J, Cook T, Clearfield M, Downs J, Pradhan A et al. Plasma homocysteine concentration, statin therapy, and the risk of first acute coronary events. Circulation 2002;105:1776-1779.
34. Spiliopoulou J, Manios E, Tsivgoulis G, Spengos K, Dolianitis K, Koroboki E et al. Attenuation of homocysteine serum levels after short-term administration of simvastatin in essential hypertensives: another pathway to cardiovascular risk reduction? Am J Hypertens 2005;18:263A.
35. Pahan K, Sheikh F, Namboodiri A, Singh I. Lovastatin and phenylacetate inhibit the induction of nitric oxide synthase and cytokines in rat primary astrocytes, microglia and macrophages. J Clin Invest 1997;100: 2672-2679.
36. Kolyada A, Fedstov A, Madias N. 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors upregulate inducible NO synthase expression and activity in vascular smooth muscle cells. Hypertension 2001;38:1024-1029.
37. Werstuck GH, Lentz SR, Dayal S, Hossain GS, Sood SK, Shi YY et al. Homocysteine-induced endoplasmic reticulum stress causes dysregulation of the cholesterol and triglyceride biosynthetic pathways. J Clin Invest 2001;107:1263-1273.